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Introduction {#s1}
============

Observational research is commonly undertaken, reported and publicised, but the role of observational studies in informing clinical practice is debated. High quality randomised controlled trials (RCTs) are usually considered to be the highest level of evidence (Level 1), with high quality cohort studies ranked immediately below this (Level 2) [@pone.0110403-Oxford1]. Some authors have suggested a broad role for observational studies because the study population may better represent the general population than in RCTs, because RCTs can be difficult or impossible to carry out for some conditions, and because systematic reviews have generally reported that results from observational studies do not differ markedly from RCTs [@pone.0110403-Benson1]--[@pone.0110403-Concato2]. However, a number of high profile examples of discrepancies between results of observational studies and subsequent RCTs have led others to suggest the role for observational studies should be limited [@pone.0110403-Lawlor1]--[@pone.0110403-Grimes1]. Observational studies suggested beneficial effects of oestrogen with progesterone on cardiovascular disease [@pone.0110403-Grodstein1], antioxidants on cancer prevention [@pone.0110403-Peto1], and folic acid/B vitamins for cardiovascular disease [@pone.0110403-Wald1], but subsequent RCTs reported either harms [@pone.0110403-Hulley1]--[@pone.0110403-Omenn1] or no benefits [@pone.0110403-Yusuf1]--[@pone.0110403-Lonn1] from these agents. Because observational studies cannot test causality, one view is that their results should be regarded as hypothesis-generating and should not influence clinical practice until these hypotheses are tested in adequately powered RCTs [@pone.0110403-Prasad1]. Others suggest that small effects seen in observational studies should not be considered credible because they are more likely to represent bias and confounding than a causal relationship [@pone.0110403-Grimes1].

One of the largest, longest and most influential observational studies is the Nurses' Health Study (NHS). The NHS began in 1976 and has subsequently followed more than 100,000 women in the original cohort study. Numerous papers in high impact biomedical journals have originated from this study. The size, duration and eminence of the NHS make it a good model to formally explore the scope, veracity and impact of data from observational analyses. In the present work, we have undertaken a systematic review of publications from the NHS. We set out to determine how many hypotheses have been explored in NHS publications, the strength of the associations reported, and how these findings align with those from RCTs on the same topics.

Methods {#s2}
=======

NHS publications {#s2a}
----------------

In November 2013, we extracted the citations of all 1235 NHS publications between 1978--2012 from the NHS website (<http://www.channing.harvard.edu/nhs/?page_id=154>). We included publications with an abstract, those in which the NHS cohort was part of the population studied, and those with an observational (case-control or cohort) study design. [Figure 1](#pone-0110403-g001){ref-type="fig"} shows the flow of studies. 28 publications did not have an abstract, 52 studies did not include the NHS cohort, and 102 publications did not report findings from observational analyses, leaving 1053 publications included in our analyses.

![Flowchart of study selection.](pone.0110403.g001){#pone-0110403-g001}

One investigator (VT) reviewed the abstracts of all eligible publications. For all analyses reported in the abstracts, we extracted information on the associations analysed by the investigators, the endpoints assessed, the independent variables for each of those endpoints, and the reported effect sizes and 95% confidence intervals (CIs). We classified each result by the strength and direction of the association reported and the level of statistical significance. Statistically significant results with an odds ratio (OR) or relative risk (RR) of ≤0.25 or ≥4 were considered strong associations, those with OR/RR of 0.25--0.5 or 2--4 were considered moderate associations, and those with OR/RR of 0.5--2 were considered weak associations [@pone.0110403-Grimes1]. When the CI for the OR/RR of a reported association included 1 but the text implied a relationship between the outcome and independent variable existed, we classified these associations as statistically non-significant.

Randomised clinical trials {#s2b}
--------------------------

We selected 3 health outcomes (breast cancer, ischaemic heart disease \[IHD\] and osteoporosis) that are important to women's health and were frequently studied in NHS publications. One investigator (VT) searched PubMed for RCTs or systematic reviews of RCTs with breast cancer, IHD and osteoporosis as the primary endpoint that evaluated similar factors to the independent variables studied in NHS publications. We used the following format in our PubMed search: health outcome AND independent variable AND random\*. We included the latest meta-analysis of RCTs identified, and when one was not available or suitable, we included all large relevant RCTs. Two investigators (VT and MB) reviewed the full texts of these meta-analyses or RCTs and extracted information on effect sizes and 95% CIs for the individual result or the pooled analyses of RCTs.

Comparison of results of NHS publications with RCT results {#s2c}
----------------------------------------------------------

We compared the effect sizes reported in the NHS publications with those from relevant RCTs, and considered them concordant when the difference between the effect sizes was ≤0.15. There is no generally accepted definition of concordance of results from studies of different designs. We chose a threshold of an absolute difference of 15% on the basis that this effect size is close to the smallest that is clinically meaningful. Smaller effect sizes are generally unlikely to be considered clinically meaningful to patients, because the absolute benefits from taking a treatment are small in this situation.

Results {#s3}
=======

NHS results {#s3a}
-----------

Associations between 61 health outcomes and 1383 independent variables were reported in the abstracts of 1053 NHS publications ([Table S1](#pone.0110403.s001){ref-type="supplementary-material"}). Many of these independent variables were reported slightly differently or were closely related in different publications and so we were able to classify them into 136 broad groups comprising closely related variables. The three most commonly tested outcomes were breast cancer, colorectal cancer and IHD, and associations were reported with these endpoints for 56, 49 and 46 broad groups of independent variables, respectively ([Table 1](#pone-0110403-t001){ref-type="table"}). In total, 2007 associations between health outcomes and independent variables were reported. Of these associations, 1433 (71.4%) were results from the NHS cohort alone, and 574 (28.6%) were from studies where the NHS cohort was pooled with other cohorts. [Figure 2](#pone-0110403-g002){ref-type="fig"} shows that 1165 (58.0%) of the 2007 associations reported were statistically significant (477 beneficial, 688 harmful), 204 (10.2%) were statistically non-significant but the abstract implied an association exists (114 beneficial, 90 harmful), and 445 (22.2%) were neutral (no association). The majority of the 204 statistically non-significant results reported effect sizes for an individual subgroup that was not statistically significant, but a test for a trend across the subgroups was statistically significant. For a further 193 (9.6%) results, an association was reported in the abstract but there was insufficient information to determine whether the association was beneficial or harmful. Among the 1165 statistically significant associations, 1002 had a reported numeric RR or OR. [Figure 3](#pone-0110403-g003){ref-type="fig"} shows that the majority of these associations, 706 (70.5%), were weak, with 246 (24.5%) associations classified as moderate, and only 50 (5.0%) classified as strong associations.

![Results of 2007 tests of associations from 1053 NHS publications.\
^a^Results were statistically non-significant but the abstract implied an association exists. ^b^An association was reported in the abstract with insufficient information to determine the strength or direction of the association.](pone.0110403.g002){#pone-0110403-g002}

![Strength of 1002 statistically significant relative risks and odds ratios reported in NHS publications.\
Associations with an odds ratio (OR) or relative risk (RR) of ≤0.25 or ≥4 were considered strong, those with OR/RR of 0.25--0.5 or 2--4 were considered moderate, and those with OR/RR of 0.5--2 were considered weak.](pone.0110403.g003){#pone-0110403-g003}

10.1371/journal.pone.0110403.t001

###### Results of 2007 associations reported in 1053 Nurses' Health Study Abstracts.

![](pone.0110403.t001){#pone-0110403-t001-1}

  Outcome                                  Publications (n)   Individual   Broad groups   Statistically significant   Statistically   No   Association        
  --------------------------------------- ------------------ ------------ -------------- --------------------------- --------------- ---- ------------- ----- -----
  **All Outcomes**                               1053            1383          136                   688                   477        90       114       445   193
  **[Individual outcomes]{.ul}**                                                                                                                              
  Breast cancer                                  209             326            56                   119                   56         17       23        134   28
  Colorectal cancer                              123             207            49                   47                    59         11       21        38    33
  Ischaemic heart disease                         98             137            46                   54                    48         8         6        13    12
  Diabetes mellitus                               55              95            32                   47                    32         3         1         8     4
  Serum markers                                   51             119            32                   40                    38         1         0         1    42
  Ovarian cancer                                  50              95            35                   24                    17         9        10        41     3
  Mortality                                       43              57            21                   28                    23         0         1         2     4
  Cognitive ability                               31              46            19                   17                    10         0         4        10     5
  Colorectal adenoma                              30              58            24                   16                    13         3         7        17     2
  Endometrial cancer                              29              53            21                   15                    13         1         5        18     1
  Skin cancer                                     29              54            14                   25                     5         7         2        11     4
  Stroke                                          28              52            26                   24                    20         2         5         0     1
  Cardiovascular disease                          25              36            22                   16                    12         2         2         3     2
  Pancreatic cancer                               24              44            19                   18                     3         2         1        20     1
  Kidney disease                                  23              42            27                   20                    12         1         3         7     1
  Hypertension                                    22              31            18                   17                    12         0         0         2     0
  Cataract                                        21              34            16                   10                    15         3         3         3     0
  Osteoporosis                                    19              33            19                   10                     8         2         1         9     3
  Rheumatoid arthritis                            18              33            19                    7                     1         7         0        17     1
  Body weight                                     18              25            16                   11                     5         0         0         2     7
  Gallstones                                      15              24            15                    9                    11         0         1         3     1
  Parkinson's disease                             13              24            17                    1                     7         2         4         9     1
  Urinary incontinence                            12              25            10                   17                     3         0         0         3     2
  General Health                                  11              19            5                    10                     2         0         0         0     9
  Lung cancer                                     11              18            11                    1                     7         1         2         6     2
  Macular degeneration                            11              16            10                    8                     4         0         0         3     1
  Cancer- general                                 10              13            8                     7                     1         0         0         4     1
  Glaucoma                                        9               19            13                    2                     4         0         0        13     0
  Kidney cancer                                   9               20            13                    5                     3         0         6         5     2
  Mental health                                   9               14            9                     6                     5         1         0         1     1
  Asthma                                          7               11            9                     5                     2         0         1         0     3
  Chronic disease                                 7               7             3                     1                     5         0         0         1     1
  Mammographic density                            7               13            2                     4                     3         0         0         7     0
  Sudden cardiac death                            7               7             7                     2                     4         1         0         0     0
  Bladder cancer                                  5               7             7                     2                     0         0         0         5     0
  Thrombotic disease                              5               8             8                     5                     0         1         0         2     0
  Brain tumor                                     5               12            9                     3                     1         1         0         6     1
  Systemic lupus erythematosus                    5               5             5                     1                     0         1         0         3     0
  Lymphoma                                        4               8             6                     3                     1         1         2         0     1
  Menarche                                        4               3             2                     0                     0         0         0         1     3
  Menopause                                       4               3             3                     1                     0         1         0         0     3
  Telomere length                                 4               7             6                     3                     3         0         0         1     0
  Urine composition                               4               13            6                     8                     4         0         0         1     0
  Dental health                                   3               4             3                     0                     0         0         0         2     2
  Dietary quality                                 3               4             3                     1                     0         0         0         1     2
  Gout                                            3               9             7                     5                     4         0         0         0     0
  Multiple sclerosis                              3               7             3                     0                     0         1         1         5     0
  Smoking                                         3               3             3                     1                     0         0         0         1     1
  Amyotrophic lateral sclerosis                   2               4             2                     2                     0         0         2         0     0
  Chronic obstructive pulmonary disease           2               2             2                     1                     0         0         0         1     0
  Ageing                                          1               1             1                     0                     1         0         0         0     0
  Barrett's esophagus                             1               2             1                     1                     0         0         0         1     0
  Bronchitis                                      1               1             1                     1                     0         0         0         0     0
  Caffeine intake                                 1               1             1                     0                     0         0         0         0     1
  Complementary Medicine                          1               3             1                     0                     0         0         0         3     0
  Connective tissue disease                       1               1             1                     0                     0         0         0         1     0
  Falls                                           1               1             1                     1                     0         0         0         0     0
  Hair colour/skin pigmentation                   1               1             1                     0                     0         0         0         0     1
  Immunologic disease                             1               1             1                     1                     0         0         0         0     0
  Insulin resistance                              1               2             1                     2                     0         0         0         0     0
  Osteoarthritis                                  1               3             2                     3                     0         0         0         0     0

In total 2007 associations were reported between 61 health outcomes and 1383 independent variables.

Results were statistically non-significant but the abstract implied an association exists.

An association was reported in the abstract with insufficient information to determine the strength or direction of the association.

[Table 2](#pone-0110403-t002){ref-type="table"} shows the journals and frequency of NHS publications. The impact of NHS publications is apparent: 30% of the publications were published in journals with impact factors \>10, and 15% were published in one of the 6 most prestigious internal medicine journals (Annals of Internal Medicine, Archives of Internal Medicine, BMJ, Lancet, JAMA, New England Journal of Medicine).

10.1371/journal.pone.0110403.t002

###### Top 20 most frequently published Journals for Nurses' Health Study publications.

![](pone.0110403.t002){#pone-0110403-t002-2}

  Journal                                          Impact factor   Number of publications
  ----------------------------------------------- --------------- ------------------------
  Cancer Epidemiology Biomarkers and Prevention         4.6                  81
  American Journal of Epidemiology                      4.8                  80
  American Journal of Clinical Nutrition                6.5                  66
  Journal of the National Cancer Institute              14                   59
  Journal of the American Medical Association           30                   50
  International Journal of Cancer                       6.2                  49
  New England Journal of Medicine                       52                   38
  Cancer Causes and Control                             3.2                  35
  Archives of Internal Medicine                         11                   33
  Cancer Research                                       8.7                  25
  Diabetes Care                                         7.7                  23
  Circulation                                           15                   22
  Annals of Internal Medicine                           14                   20
  CA-A Cancer Journal for Clinicians                    153                  18
  Journal of Clinical Oncology                          18                   15
  Nature Genetics                                       35                   13
  Breast Cancer Research                                5.9                  12
  Carcinogenesis                                        5.6                  12
  Human Molecular Genetics                              7.7                  12
  PLoS One                                              3.7                  12

Comparisons between NHS findings and RCT results {#s3b}
------------------------------------------------

The results from NHS publications and relevant RCTs are summarised in [Table 3](#pone-0110403-t003){ref-type="table"} for breast cancer, [Table 4](#pone-0110403-t004){ref-type="table"} for IHD, and [Table 5](#pone-0110403-t005){ref-type="table"} for osteoporosis. Of the 49 associations in NHS publications for these 3 outcomes, 16 were not statistically significant, and 30 statistically significant associations were classified as weak, 3 as moderate, and 0 as strong. For breast cancer, NHS publications reported associations with 56 broad groups of predictive factors. Of these factors, 8 have been tested in RCTs [@pone.0110403-Hulley1], [@pone.0110403-Rossouw1], [@pone.0110403-Bristow1]--[@pone.0110403-Lee1], and 6/24 (25%) of effect sizes in NHS publications [@pone.0110403-Shin1]--[@pone.0110403-Hunter1] were concordant with those from RCTs. For IHD, NHS publications reported associations with 46 broad groups of predictive factors, of which 7 have been tested in RCTs [@pone.0110403-Myung1]--[@pone.0110403-Yang1]. 2/19 (10.5%) of effect sizes in NHS publications [@pone.0110403-Osganian1]--[@pone.0110403-Stampfer3] were concordant with those from RCTs. For osteoporosis, NHS publications reported associations with 19 broad groups of predictive factors, of which 4 have been tested in RCTs [@pone.0110403-Reid1]--[@pone.0110403-Stevenson1]. 1/5 (20%) of effect sizes in NHS publications [@pone.0110403-Feskanich1]--[@pone.0110403-Feskanich4] were concordant with those from RCTs. Of the 39 discordant results for these 3 endpoints, 29 NHS results were more positive (ie a smaller RR or OR) than the RCT results. 8 of the 10 discordant results where the NHS results were more negative (ie a larger RR or OR) than the RCT results were from NHS publications examining the relationship between oestrogen and breast cancer.

10.1371/journal.pone.0110403.t003

###### Results of Nurses' Health Study and related randomised clinical trials for breast cancer.

![](pone.0110403.t003){#pone-0110403-t003-3}

  Randomised controlled trials                                     Nurses' Health Study Publications                                                                                                                                    
  ------------------------------------------------------ ------------------------------------------------------ -------------- ---------------------------------------- ------------------------------------------------ -------------- -----
  Bristow 2013 [@pone.0110403-Bristow1]                                 Meta-analysis of 6 RCTs                      1.01           Shin 2002[@pone.0110403-Shin1]                        Cohort study                        0.69       No
                                                                         V: Calcium supplements                  (0.64--1.59)                                                       V: Dairy calcium intake               (0.48--0.98)  
                                                                            O: Breast cancer                                                                                     O: Premenopausal breastcancer                          
  **Beta-carotene**                                                        **Beta-carotene**                                                                                                                                            
  Druesne-Pecollo                                                       Meta-analysis of 4 RCTs                      0.96         Tamimi 2005[@pone.0110403-Tamimi1]                   Case-control study                     0.73       No
  2009 [@pone.0110403-DruesnePecollo1]                              V: Beta-carotenesupplementation              (0.85--1.10)                                                       V: Plasma beta-carotene               (0.53--1.02)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                
                                                                                                                                   Zhang 2012[@pone.0110403-Zhang1]           Pooled analysis of 18 cohortstudies             0.84       Yes
                                                                                                                                                                                    V: Beta-carotene intake               (0.77--0.93)  
                                                                                                                                                                                  O: ER-negative breast cancer                          
  **Folate**                                                                   **Folate**                                                                                                                                               
  Vollset 2013 [@pone.0110403-Vollset1]                                 Meta-analysis of 13 RCTs                     0.89          Zhang 1999[@pone.0110403-Zhang2]                       Cohort study                        0.55       No
                                                                      V: Folic acidsupplementation               (0.66--1.20)                                                           V: Folate intake                  (0.39--0.76)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                
                                                                                                                                   Zhang 2005[@pone.0110403-Zhang3]                       Cohort study                         1         Yes
                                                                                                                                                                                        V: Folate intake                  (0.89--1.14)  
                                                                                                                                                                                  O: ER-positive breast cancer                          
                                                                                                                                   Zhang 2005[@pone.0110403-Zhang3]                       Cohort study                        0.81       Yes
                                                                                                                                                                                        V: Folate intake                  (0.66--0.99)  
                                                                                                                                                                                  O: ER-negative breast cancer                          
  **Aspirin**                                                                 **Aspirin**                                                                                                                                               
  Cook 2005 [@pone.0110403-Cook1]                                       Women's Health Study RCT                     0.98           Egan 1996[@pone.0110403-Egan1]                        Cohort study                        1.03       Yes
                                                                          V: Low-dose aspirin                    (0.87--1.09)                                                      V: ≥2 tablets aspirin/week             (0.95--1.12)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                
                                                                                                                                  Holmes 2010[@pone.0110403-Holmes1]        Cohort study of stages 1--3 breastcancer          0.36       No
                                                                                                                                                                                   V: Aspirin 6--7 days/week              (0.24--0.54)  
                                                                                                                                                                                   O: Breast cancer mortality                           
                                                                                                                                  Holmes 2010[@pone.0110403-Holmes1]        Cohort study of stages 1--3 breastcancer          0.57       No
                                                                                                                                                                                   V: Aspirin 6--7 days/week              (0.39--0.82)  
                                                                                                                                                                                     O: Distant recurrence                              
                                                                                                                                  Holmes 2011[@pone.0110403-Holmes2]      Cohort study of COX-2-positivebreast cancer         0.64       No
                                                                                                                                                                                           V: Aspirin                     (0.43--0.96)  
                                                                                                                                                                                   O: Breast cancer mortality                           
                                                                                                                                  Holmes 2011[@pone.0110403-Holmes2]      Cohort study of COX-2-positivebreast cancer         0.57       No
                                                                                                                                                                                           V: Aspirin                     (0.44--0.74)  
                                                                                                                                                                                     O: Distant recurrence                              
  **Postmenopausal hormones -- oestrogen**                      **Postmenopausal hormones -- oestrogen**                                                                                                                                
  Anderson 2004[@pone.0110403-Anderson1]                              Women's HealthInitiative RCT                   0.77        Colditz 1990[@pone.0110403-Colditz1]                     Cohort study                        1.36       No
                                                                              V: Oestrogen                       (0.59--1.01)                                                             V: Oestrogen                    (1.11--1.67)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                
                                                                                                                                 Colditz 1992[@pone.0110403-Colditz2]                     Cohort study                        1.42       No
                                                                                                                                                                                          V: Oestrogen                    (1.19--1.70)  
                                                                                                                                                                                        O: Breast cancer                                
                                                                                                                                 Colditz 1995[@pone.0110403-Colditz3]                     Cohort study                        1.32       No
                                                                                                                                                                                          V: Oestrogen                    (1.14--1.54)  
                                                                                                                                                                                        O: Breast cancer                                
                                                                                                                                 Colditz 2000[@pone.0110403-Colditz4]                     Cohort study                        1.23       No
                                                                                                                                                                               V: Oestrogen use from ages50--60 y         (1.06--1.42)  
                                                                                                                                                                         O: Cumulative risk of breastcancer to age 70 y                 
                                                                                                                                    Chen 2006[@pone.0110403-Chen1]         Cohort study among women withhysterectomy          1.42       No
                                                                                                                                                                                   V: Oestrogen use for ≥20 y             (1.13--1.77)  
                                                                                                                                                                                        O: Breast cancer                                
                                                                                                                                    Chen 2006[@pone.0110403-Chen1]         Cohort study among women withhysterectomy          1.48       No
                                                                                                                                                                                   V: Oestrogen use for ≥15 y             (1.05--2.07)  
                                                                                                                                                                            O: ER-positive/PR-positive breastcancer                     
  **Postmenopausal hormones -- oestrogen + progestin**    **Postmenopausal hormones -- oestrogen + progestin**                                                                                                                          
  Hulley 1998[@pone.0110403-Hulley1]                                  Heart andoestrogen/progestin                   1.3         Colditz 1992[@pone.0110403-Colditz2]                     Cohort study                        1.54       No
                                                                         replacement study RCT                   (0.77--2.19)                                                       V: Oestrogen + progestin              (0.99--2.39)  
                                                                        V: Oestrogen + progestin                                                                                        O: Breast cancer                                
                                                                     O: Postmenopausal breastcancer                                                                                                                                     
  Rossouw 2002[@pone.0110403-Rossouw1]                                Women's Health InitiativeRCT                   1.26        Colditz 1995[@pone.0110403-Colditz3]                     Cohort study                        1.41       Yes
                                                                        V: Oestrogen + progestin                 (1.00--1.59)                                                       V: Oestrogen + progestin              (1.15--1.74)  
                                                                     O: Postmenopausal breastcancer                                                                                     O: Breast cancer                                
                                                                                                                                 Colditz 2000[@pone.0110403-Colditz4]                     Cohort study                        1.67       No
                                                                                                                                                                                    V: Oestrogen + progestin              (1.18--2.36)  
                                                                                                                                                                         O: Cumulative risk of breastcancer to age 70 y                 
  **Statins**                                                                 **Statins**                                                                                                                                               
  Pfeffer 2002[@pone.0110403-Pfeffer1]                                           3 RCTs                               2         Eliassen 2005[@pone.0110403-Eliassen1]                    Cohort study                        0.91       No
                                                                             V: Pravastatin                      (0.97--4.11)                                                              V: Statins                     (0.76--1.08)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                
  **Vitamin D**                                                              **Vitamin D**                                                                                                                                              
  Sperati 2013[@pone.0110403-Sperati1]                                  Meta-analysis of 2 RCTs                      1.11           Shin 2002[@pone.0110403-Shin1]                        Cohort study                        0.72       No
                                                                        V: Vitamin D supplements                 (0.74--1.68)                                                         V: Vitamin D intake                 (0.55--0.94)  
                                                                            O: Breast cancer                                                                                     O: Premenopausal breastcancer                          
                                                                                                                                           Bertone-Johnson                             Case-control study                     0.73       No
                                                                                                                                 2005 [@pone.0110403-BertoneJohnson1]        V: Plasma levels of25-hydroxyvitamin D       (0.49--1.07)  
                                                                                                                                                                                        O: Breast cancer                                
  **Vitamin E**                                                              **Vitamin E**                                                                                                                                              
  Lee 2005[@pone.0110403-Lee1]                                          Women's Health Study RCT                      1           Hunter 1993[@pone.0110403-Hunter1]                      Cohort study                        0.99       Yes
                                                                        V: Vitamin E supplements                 (0.90--1.12)                                                         V: Vitamin E intake                 (0.83--1.19)  
                                                                            O: Breast cancer                                                                                            O: Breast cancer                                

CI = confidence interval; RCT = randomised controlled trial; V = independent variable; O = health outcome or endpoint; ER = oestrogen receptor; PR = progesterone receptor.

10.1371/journal.pone.0110403.t004

###### Results of Nurses' Health Study and related randomised clinical trials for ischaemic heart disease.

![](pone.0110403.t004){#pone-0110403-t004-4}

  Randomised controlled trials                                         Nurses' Health Study Publications                                                                                                                              
  ---------------------------------------------------------- ------------------------------------------------------ --------------------------------- ---------------------------------------------------------------- -------------- -----
  Myung                                                                               0.96                                      Osganian                                        Cohort study                                0.74       No
  2013 [@pone.0110403-Myung1]                                                     (0.92--1.04)                       2003 [@pone.0110403-Osganian1]                       V: Beta-carotene intake                       (0.59--0.93)  
                                                                                                                                                                         O: Coronary artery disease                                   
  **Omega-3 fatty acids**                                                   **Omega-3 fatty acids**                                                                                                                                   
  Kotwal                                                                              0.86                             Hu 1999 [@pone.0110403-Hu1]                              Cohort study                                0.55       No
  2012 [@pone.0110403-Kotwal1]                                                    (0.67--1.11)                                                                         V: Alpha-linolenic acid intake                   (0.32--0.94)  
                                                                                                                                                                      O: Fatal ischaemic heart disease                                
                                                                                                                                                                                                                                      
                                                                                                                       Hu 2002 [@pone.0110403-Hu2]                              Cohort study                                0.67       No
                                                                                                                                                                        V: Omega-3 fatty acid intake                    (0.55--0.81)  
                                                                                                                                                                         O: Coronary heart disease                                    
                                                                                                                       Hu 2003 [@pone.0110403-Hu3]                    Cohort study of type 2 diabetes                       0.69       No
                                                                                                                                                                  V: Long-chain omega-3 fatty acid intake               (0.47--1.03)  
                                                                                                                                                                         O: Coronary heart disease                                    
  **Folate**                                                                       **Folate**                                                                                                                                         
  Myung                                                                               0.99                           Rimm 1998 [@pone.0110403-Rimm1]                            Cohort study                                0.69       No
  2013 [@pone.0110403-Myung1]                                                     (0.95--1.02)                                                                                V: Folate intake                          (0.55--0.87)  
                                                                                                                                                                         O: Coronary heart disease                                    
  **Aspirin**                                                                     **Aspirin**                                                                                                                                         
  Berger                                                                              0.86                                       Manson                                         Cohort study                                0.75       Yes
  2011 [@pone.0110403-Berger1]                                                    (0.74--1.00)                        1991 [@pone.0110403-Manson1]                          V: 1--6 aspirin/week                        (0.58--0.99)  
                                                                                                                                                                          O: Myocardial infarction                                    
  **Postmenopausal hormones -- oestrogen**                          **Postmenopausal hormones -- oestrogen**                                                                                                                          
  Yang                                                                                0.93                           Bain 1981 [@pone.0110403-Bain1]                         Case-control study                             0.7        No
  2013 [@pone.0110403-Yang1]                                                      (0.80--1.08)                                                                                  V: Oestrogen                             (0.5--1.1)   
                                                                                                                                                                          O: Myocardial infarction                                    
  Yang                                                                                0.95                                      Stampfer                                        Cohort study                                0.3        No
  2013 [@pone.0110403-Yang1]                                                      (0.78--1.15)                       1985 [@pone.0110403-Stampfer1]                             V: Estorgen                              (0.2--0.6)   
                                                                                                                                                                            O: Coronary disease                                       
                                                                                                                                Stampfer                                        Cohort study                                0.56       No
                                                                                                                     1991 [@pone.0110403-Stampfer2]                             V: Oestrogen                            (0.40--0.80)  
                                                                                                                                                                            O: Coronary disease                                       
                                                                                                                                Grodstein                                       Cohort study                                0.61       No
                                                                                                                     2000 [@pone.0110403-Grodstein2]   V: Hormone therapy - oestrogen[a](#nt105){ref-type="table-fn"}   (0.52--0.71)  
                                                                                                                                                                             O: Coronary events                                       
                                                                                                                                Grodstein                                       Cohort study                                0.54       No
                                                                                                                     2000 [@pone.0110403-Grodstein2]              V: 0.625 mg/d oral conjugated oestrogen               (0.44--0.67)  
                                                                                                                                                                             O: Coronary events                                       
                                                                                                                                Grodstein                        Cohort study of previous coronary disease                  1.25       No
                                                                                                                     2001 [@pone.0110403-Grodstein3]                   V: Short-term use of oestrogen                   (0.78--2.00)  
                                                                                                                                                                 O: Recurrent coronary heart disease events                           
                                                                                                                                Grodstein                        Cohort study of previous coronary disease                  0.38       No
                                                                                                                     2001 [@pone.0110403-Grodstein3]                   V: Long-term use of oestrogen                    (0.22--0.66)  
                                                                                                                                                                 O: Recurrent coronary heart disease events                           
                                                                                                                                Grodstein                                       Cohort study                                0.66       No
                                                                                                                     2006 [@pone.0110403-Grodstein4]              V: Oestrogen (beginning near menopause)               (0.54--0.80)  
                                                                                                                                                                         O: Coronary heart disease                                    
                                                                                                                                Grodstein                                       Cohort study                                0.87       Yes
                                                                                                                     2006 [@pone.0110403-Grodstein4]           V: Oestrogen (beginning \>10 yafter menopause)           (0.69--1.10)  
                                                                                                                                                                         O: Coronary heart disease                                    
  **Postmenopausal hormones --** **oestrogen + progestin**    **Postmenopausal hormones -- oestrogen + progestin**                                                                                                                    
  Yang                                                                                1.07                                      Grodstein                                       Cohort study                                0.72       No
  2013 [@pone.0110403-Yang1]                                                      (0.91--1.26)                       2006 [@pone.0110403-Grodstein4]         V: Oestrogen + progestin(beginning near menopause)         (0.56--0.92)  
                                                                                                                                                                         O: Coronary heart disease                                    
  Yang                                                                                1.09                                      Grodstein                                       Cohort study                                0.9        No
  2013 [@pone.0110403-Yang1]                                                      (0.85--1.41)                       2006 [@pone.0110403-Grodstein4]             V: Oestrogen + progestin (beginning \>10 y             (0.62--1.29)  
                                                                                                                                                                              after menopause)                                        
                                                                                                                                                                         O: Coronary heart disease                                    
  **Vitamin B**                                                                  **Vitamin B**                                                                                                                                        
  Myung                                                                               0.96                           Rimm 1998 [@pone.0110403-Rimm1]                            Cohort study                                0.67       No
  2013 [@pone.0110403-Myung1]                                                     (0.92--1.01)                                                                              V: Vitamin B6 intake                        (0.53--0.85)  
                                                                                                                                                                         O: Coronary heart disease                                    
  **Vitamin E**                                                                  **Vitamin E**                                                                                                                                        
  Myung                                                                               0.97                                      Stampfer                                        Cohort study                                0.66       No
  2013 [@pone.0110403-Myung1]                                                     (0.94--1.01)                       1993 [@pone.0110403-Stampfer3]                         V: Vitamin E intake                         (0.50--0.87)  
                                                                                                                                                                         O: Major coronary disease                                    

The type of hormone therapy was not described in the paper, but is most likely to be oestrogen without progesterone.

CI = confidence interval; RCT = randomised controlled trial; V = independent variable; O = health outcome or endpoint.

10.1371/journal.pone.0110403.t005

###### Results of Nurses' Health Study and related randomised clinical trials for osteoporosis.

![](pone.0110403.t005){#pone-0110403-t005-5}

  Randomised controlled trials             Nurses' Health Study Publications                                                                                                                                      
  --------------------------------------- ----------------------------------- ---------------------------------------------- --------------------------------- ----------------------------------- -------------- -------------------------------------
  Reid 2014 [@pone.0110403-Reid1]               Meta-analysis of 5 RCTs                            1.61                                  Feskanich                        Cohort study                  1.45                       No
                                                V: Calcium supplements                         (0.91--2.85)                   1997 [@pone.0110403-Feskanich1]           V: Calcium intake           (0.87--2.43)  
                                                    O: Hip fracture                                                                                                      O: Hip fracture                          
                                                                                                                                         Feskanich                        Cohort study                  0.96                       No
                                                                                                                              2003 [@pone.0110403-Feskanich2]   V: ≥1200 mg/d total calciumintake   (0.68--1.34)  
                                                                                                                                                                         O: Hip fracture                          
  **Fluoride**                                       **Fluoride**                                                                                                                                                 
  Vestergaard                                   Meta-analysis of 8 RCTs                            0.8                                   Feskanich                     Case-control study               0.8                        Yes
  2008 [@pone.0110403-Vestergaard1]            V: Fluoride formulations                         (0.5--1.4)                    1998 [@pone.0110403-Feskanich3]          V: Toenail fluoride           (0.2--4.0)   
                                               O: Non-vertebral fracture                                                                                                 O: Hip fracture                          
                                                                                                                                         Feskanich                     Case-control study               1.6                        No
                                                                                                                              1998 [@pone.0110403-Feskanich3]          V: Toenail fluoride           (0.8--3.1)   
                                                                                                                                                                       O: Forearm fracture                        
  **Vitamin D**                                      **Vitamin D**                                                                                                                                                
  Avenell 2009 [@pone.0110403-Avenell1]         Meta-analysis of 9 RCTs                            1.15                                  Feskanich                        Cohort study                  0.63                       No
                                               V: Vitamin D supplements                        (0.99--1.33)                   2003 [@pone.0110403-Feskanich2]    V: ≥12.5 mcg/d Vitamin Dintake     (0.42--0.94)  
                                                    O: Hip fracture                                                                                                      O: Hip fracture                          
  **Vitamin K**                                      **Vitamin K**                                                                                                                                                
  Stevenson                                     Meta-analysis of 3 RCTs                            0.27                                  Feskanich                        Cohort study                  0.7        N/A[a](#nt107){ref-type="table-fn"}
  2009 [@pone.0110403-Stevenson1]              V: Vitamin K2 supplements       (0.03--2.38)[a](#nt107){ref-type="table-fn"}   1999 [@pone.0110403-Feskanich4]          V: Vitamin K intake          (0.53--0.93)  
                                                    O: Hip fracture                                                                                                      O: Hip fracture                          

Based on 3 hip fractures only in RCTS. Therefore, insufficient data for comparison between studies.

CI = confidence interval; RCT = randomised controlled trial; V = independent variable; O = health outcome or endpoint; N/A = Not available.

Discussion {#s4}
==========

NHS publications report a very large number of associations between health outcomes and independent variables. Only 1 in 5 associations was reported as neutral (no association). Of the statistically significant associations, only 5% were strong associations (OR/RR ≤0.25 or ≥4), with 70% of effect sizes being weak (OR/RR between 0.5 and 2.0). Few of the associations have been tested in RCTs and, where relevant RCTs have been reported, only 1 in 5 NHS study results was concordant with the RCT result. Despite this, NHS publications were frequently published in high impact journals.

More than 2000 associations from this single study were reported in the abstracts of publications we reviewed. This is likely to be a substantial underestimate of the actual number of associations examined, because many results will have only been reported in the text or tables of the full article or will not have been reported. The large number of statistical tests raises concerns about false positive results. None of the abstracts highlighted this possibility, reported analyses adjusted for multiple statistical testing, or mentioned the number of analyses previously conducted in the NHS cohort.

1358 results (68%) in NHS publication abstracts were either statistically significant or reported as though an association existed. It is difficult to estimate the likely number of false positives amongst these results. If all of the 2007 associations examined were of unrelated variables and there was no relationship between the health outcomes and these variables, about 100 results (5%) would be statistically significant due to chance. However, many of the variables examined were closely related which would decrease the total number of independent tests. On the other hand, it is likely that the results reported in the abstract are only a small proportion of the total statistical tests conducted (either reported in the full article or not reported) which would substantially increase the total number of independent tests. Furthermore, statistically significant results are more likely to be reported in the abstract than non-significant results. Given the likely bias toward significant results and the very large number of statistical tests performed, it seems reasonable to conclude that a substantial proportion of results were false positives. This concern was not raised in any of the abstracts.

The strength of associations reported in observational studies is often viewed as an indicator of the credibility of the association [@pone.0110403-Grimes1], [@pone.0110403-Ioannidis2]--[@pone.0110403-Shapiro2]. Associations with OR or RR ≥4 or ≤0.25 are considered strong and more likely to be reliable in the absence of significant bias [@pone.0110403-Grimes1], [@pone.0110403-Shapiro1], [@pone.0110403-Shapiro2]. However, where the association is weak or moderate, such results should be viewed with scepticism. Effect sizes may be inflated, observational studies are limited by selection bias, confounding, and methodological weaknesses in their study design and analysis, and large observational studies can produce implausibly precise estimates of effect sizes that are highly statistically significant but clinically unimportant [@pone.0110403-Grimes1], [@pone.0110403-Ioannidis2]--[@pone.0110403-Shapiro2]. Only 5% of results reported in NHS publications were strong associations. Despite this, a very large number of NHS papers were published in high-impact general medical and speciality journals. A recent survey reported that only 14% of publications of observational studies in high impact medical journals called for RCTs to support their findings, with the majority making explicit recommendations regarding clinical practice based upon the observational study findings [@pone.0110403-Prasad1]. Taken together, these findings suggest that many journals, including high impact journals, place a low importance on the strength of an association or the non-randomised nature of the study and hence the credibility of the association when evaluating observational studies for publication. In addition, since clinical research findings published in prominent journals influence clinical behaviour, our findings suggest that clinical practice might often be driven by false positive results from observational studies.

We compared findings from NHS publications and RCTs for 3 important health outcomes that were studied commonly in NHS publications. Results of 496 associations between breast cancer, IHD, and osteoporosis and independent variables were reported in 326 publications. However, few RCTs examining the relationship between these outcomes and the independent variables have been undertaken. Thus, we identified RCTs for only 19 of these broad groups of variables for these 3 outcomes, and the concordance between the results of the RCTs and the NHS results was poor. The reasons for the small number of RCTs are not clear. It is possible that investigators do not view the NHS results as credible because of the small effect sizes, and thus have not chosen to examine their findings in RCTs, but this seems unlikely. A possible explanation is that RCTs are more difficult, more expensive, and take longer to conduct than new analyses of the NHS, or comparable analyses of other observational datasets. In addition, the volume of hypotheses generated -- about 30 NHS papers eligible for our analysis were published annually -- and the small effect sizes reported means that an impractically large number of very large RCTs would be needed to test all the associations reported. About 60% of associations reported by NHS studies suggested a harmful effect of the independent variable on the outcome. This is another possible explanation for the small number of RCTs as directly assessing potential harms in an RCT is likely to be unattractive to researchers, ethics committees, funding bodies, and participants. However, potential harms identified in observational studies can usually be indirectly assessed in RCTs, by exploring whether interventions that reduce the potential harmful exposure improve health outcomes. If reduction of a potentially harmful exposure has no impact on health outcomes, this suggests that harm from the exposure is spurious and not clinically relevant.

Previous systematic comparisons of the results of observational studies and RCTs have reported that pooled results from observational studies generally do not differ markedly from pooled results from RCTs [@pone.0110403-Benson1]--[@pone.0110403-Ioannidis1]. However, within these pooled analyses, there were marked variations in individual results, discrepancies did occur, and differences in estimated magnitude of treatment effect were common [@pone.0110403-Concato1], [@pone.0110403-Ioannidis1]. There was agreement between the results of NHS publications and relevant RCTs for only 10--25% of analyses for the 3 outcomes we assessed. The low rate of concordance likely reflects the propensity of observational analyses to generate inaccurate estimates of effect, as a result of confounding and bias. Other contributing factors might be that our definition of concordance was quite stringent, or that the factors studied in RCTs were not always identical to those studied in NHS publications (eg. calcium supplements vs. dietary calcium intake).

In summary, we found that a very large number of associations have been reported in NHS publications, but 95% were weak or moderate in strength, and therefore unlikely to be causal. Few of these associations have been tested in RCTs, and where they have been, agreement between NHS and RCT findings is poor. Clinicians interpreting the findings of observational studies such as the NHS should be aware of the possibility that multiple statistical tests have been undertaken with the resulting likelihood of false positive results, and of the lack of credibility for associations where the effect size is small. The low concordance of NHS findings with RCT findings suggests that clinical practice should not be informed by observational studies, and that findings from observational studies should not necessarily lead to confirmatory RCTs being conducted, especially when the effect size is small. Reporting of observational studies would be improved by including the total number of associations ever tested in the study, the proportions of statistically significant results previously published, and whether previous findings from the observational study are concordant with RCTs.
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